MannKind (MNKD) said Wednesday it received clearance from Japan's Pharmaceuticals and Medical Devices Agency to begin the phase 3 trial of its Clofazimine Inhalation Suspension treatment for lung disease.
The study is now cleared in four countries including Japan, MannKind said, adding that it expects approval from Taiwan in Q4.
Price: 6.70, Change: +0.14, Percent Change: +2.13
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.